摘要
目的评价重组组织型纤溶酶原激活剂(rt-PA)治疗急性脑梗死的疗效及安全性。方法128例发病<6h的急性脑梗死患者随机分为治疗组和对照组。对照组应用常规治疗方法;治疗组在常规治疗方法的基础上采用rt-PA治疗,两组治疗前及治疗后90d时均采用脑卒中患者临床神经功能缺损程度评分标准(CSS)及Barthel指数(BI)评价并对比评价结果。结果治疗前两组患者CSS评分和BI〔CSS评分对照组(22±3)分,治疗组(23±3)分;BI对照组(53±11),治疗组(54±13)〕比较差异无统计学意义(P>0.05),而治疗后〔CSS评分对照组(16±5)分,治疗组(8±4)分;BI对照组(60±13),治疗组(84±14)〕两组间差异有统计学意义(P<0.01);两组疗效间差异有统计学意义(P<0.05);治疗组发生脑出血2例,泌尿道出血合并牙龈出血1例,牙龈出血1例。对照组发生脑出血1例,泌尿道出血合并牙龈出血1例,牙龈出血2例。结论急性脑梗死发病<6h应用rt-PA治疗安全、有效。
Objective To evaluate the efficacy and safety of recombinant tissue plasminogen activator(rTPA)in acute cerebral infarction(ACI).Methods One hundred twenty-eight ACI patients(stroke onset within 6 h)were randomized into treatment and control groups.The control were treated with conventional therapy,and the treatment group with additional rt-PA besides conventional.The results were comparatively evaluated by CSS and Barthel index(BI),before treatment or day 90 after.Results There was no significant different...
出处
《中国全科医学》
CAS
CSCD
北大核心
2009年第8期651-652,共2页
Chinese General Practice
基金
湖南省科技计划项目(2007FJ3092)
关键词
组织型纤溶酶原激活物
脑梗死
血栓溶解疗法
Recombinant tissue plasminogen activator
Cerebral infarction
Thrombolytic therapy
